Palvella Therapeutics

Yahoo Finance • 14 days ago

Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 8th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roiva... Full story

Yahoo Finance • 16 days ago

Eli Lilly and Company (LLY): One of the Top Low Risk High Growth Stocks?

We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Eli Lilly and Company (NYSE:LLY) ranks 2nd on this list. Eli Lilly and Company (NYSE:LLY) is often referred to as the leading contender to become the first trill... Full story

Yahoo Finance • last month

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therap... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Palvella Therapeutics Inc. Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth f... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved t... Full story

Yahoo Finance • 2 months ago

Palvella Prices $200 Mln Upsized Offering To Advance Late-Stage QTORIN Pipeline

(RTTNews) - Palvella Therapeutics, Inc. (PVLA) has priced an upsized public offering of 1.6 million shares of common stock at $125.00 per share, with expected gross proceeds of $200 million before underwriting discounts and expenses. Unde... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics Announces Pricing of Upsized Public Offering

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstrating a statistically significant 2.13-poi... Full story

Yahoo Finance • 3 months ago

Stocks Settle Higher as AI Disruption Fears Ease

The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.09%.  March E-mini S&P futures (ESH26) rose +0.76%, and March... Full story

Yahoo Finance • 3 months ago

Stocks Rally as AI-Fueled Worries Ease

The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.75%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.90%.  March E-mini S&P futures (ESH26) are up +0.45%, and March E-mini Nasdaq f... Full story

Yahoo Finance • 3 months ago

Stocks Rebound as Software Stocks Recover

The S&P 500 Index ($SPX) (SPY) today is up +0.17%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.47%.  March E-mini S&P futures (ESH26) are up +0.20%, and March E-mini Nasdaq f... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations 

WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of a standardized, FDA... Full story

Yahoo Finance • 5 months ago

Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Outperform rating on the shares after the company reported the Phase 2 TOIVA readout for Qtorin rapamycin in cutaneous venous malform... Full story

Yahoo Finance • 5 months ago

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

73% of trial participants (11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall cVM-IGA) at Week 12; 67% of trial participants (10/15 participants) rated as “Much Improved” (+2)... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients QTORIN™ pitavas... Full story

Yahoo Finance • 7 months ago

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Second year proceeds granted following FDA review of annual performance progress report on Phase 3 SELVA single-arm, baseline-controlled trial; up to $2.6 million in non-dilutive funding anticipated over the grant period Top-line data fro... Full story

Yahoo Finance • 7 months ago

These Were the Russell 2000 Stocks That Dominated In Q3 2025

The small cap-focused Russell 2000 index has spent years lagging behind the larger S&P 500 and Nasdaq 100 indexes, but in third-quarter 2025 it took a big leap back to parity with large caps. Thanks to interest-rate-cut bets and optimism... Full story

Yahoo Finance • 8 months ago

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.... Full story